The Role of TANK as a Drug Target and Biomarker (G10010)
The Role of TANK as a Drug Target and Biomarker
In the realm of drug development and personalized medicine, the identification of reliable drug targets and biomarkers plays a crucial role. These key entities enable the development of targeted therapies and aid in patient stratification and monitoring. One such protein, TANK, has gained considerable attention in recent years due to its multifaceted role as both a potential drug target and a biomarker for various diseases.
TANK, also known as TRAF family member-associated NF-kappa-B activator, is a pivotal adaptor protein involved in regulating key signaling pathways. It belongs to the TRAF (TNF receptor-associated factor) family, which plays a critical role in cellular response to extracellular signals and orchestrating numerous biological processes.
Within the complex cellular signaling network, TANK acts as a scaffold for the interactions between tumor necrosis factor (TNF) receptors and TRAF proteins. Through these protein-protein interactions, TANK modulates the activation of nuclear factor-kappa B (NF-魏B) pathway, a signaling cascade that affects various cellular processes, including inflammation, immunity, and cell survival.
Therapeutic Potential of TANK
Due to its central role in key signaling pathways, TANK has emerged as an attractive drug target. Manipulating TANK levels or interfering with its interactions could potentially regulate NF-魏B signaling, which has been implicated in the development and progression of various diseases, including cancer, autoimmune disorders, and inflammatory conditions.
In cancer, the dysregulation of NF-魏B signaling is frequently observed, promoting tumor growth, survival, and resistance to therapy. Targeting TANK could present a novel approach to inhibit NF-魏B activation selectively within cancer cells, thereby inhibiting their survival and proliferation. Additionally, TANK modulation could potentially enhance the efficacy of conventional cancer therapies, such as chemotherapeutic agents or radiation.
Autoimmune disorders, characterized by an overactive immune response, also show dysregulated NF-魏B signaling. By targeting TANK, researchers aim to restore the balance between pro-inflammatory and anti-inflammatory responses, potentially ameliorating the symptoms and progression of these diseases. Furthermore, TANK inhibition could potentially reduce the immunogenicity of host cells in organ transplantation, improving graft survival rates.
Inflammatory conditions, such as rheumatoid arthritis and inflammatory bowel disease, are marked by chronic inflammation resulting from sustained NF-魏B activation. TANK has been identified as a key regulator of these inflammatory processes, making it an intriguing target for therapeutic intervention. Modulating TANK expression or activity could potentially alleviate the inflammatory burden in affected tissues, leading to improved clinical outcomes.
TANK as a Biomarker
Besides its potential as a drug target, TANK has also shown promise as a biomarker for various diseases. Biomarkers are measurable indicators that provide insight into the physiological, pathological, or pharmacological processes occurring in an individual. They play a crucial role in disease diagnosis, prognosis, and monitoring treatment response.
Studies have identified altered TANK expression levels in different diseases, suggesting its potential as a diagnostic biomarker. For example, increased TANK expression has been observed in certain cancers, including breast, lung, and colorectal cancer. Elevated TANK levels have also been associated with poorer prognosis in these cancers, highlighting its potential as a prognostic biomarker. Additionally, TANK expression has shown promise as a predictive biomarker in cancer, indicating the likelihood of therapy response.
In autoimmune disorders, altered TANK expression has been reported in patients compared to healthy individuals. By measuring TANK levels, clinicians could potentially improve disease diagnosis and predict treatment response. Moreover, monitoring TANK expression over time in autoimmune patients could offer valuable insights into disease progression and help guide therapeutic decisions.
Inflammatory conditions, characterized by chronic inflammation, also exhibit altered TANK expression patterns. By measuring TANK levels in patients, clinicians could potentially assess disease severity and monitor treatment response. TANK may serve as a valuable tool to tailor treatment strategies and optimize patient outcomes.
In the rapidly evolving field of drug development and personalized medicine, TANK emerges as an intriguing protein with both therapeutic and biomarker potential. Its central role in regulating NF-魏B signaling pathways makes it an attractive drug target for various diseases, ranging from cancer to autoimmune disorders and inflammatory conditions. Additionally, alterations in TANK expression levels hold promise as diagnostic, prognostic, and predictive biomarkers, aiding in disease management and patient stratification. Further research and validation are necessary to fully exploit the potential of TANK in improving patient outcomes and advancing personalized medicine.
Protein Name: TRAF Family Member Associated NFKB Activator
Functions: Adapter protein involved in I-kappa-B-kinase (IKK) regulation which constitutively binds TBK1 and IKBKE playing a role in antiviral innate immunity. Acts as a regulator of TRAF function by maintaining them in a latent state. Blocks TRAF2 binding to LMP1 and inhibits LMP1-mediated NF-kappa-B activation. Negatively regulates NF-kappaB signaling and cell survival upon DNA damage (PubMed:25861989). Plays a role as an adapter to assemble ZC3H12A, USP10 in a deubiquitination complex which plays a negative feedback response to attenuate NF-kappaB activation through the deubiquitination of IKBKG or TRAF6 in response to interleukin-1-beta (IL1B) stimulation or upon DNA damage (PubMed:25861989). Promotes UBP10-induced deubiquitination of TRAF6 in response to DNA damage (PubMed:25861989). May control negatively TRAF2-mediated NF-kappa-B activation signaled by CD40, TNFR1 and TNFR2
More Common Targets
A2M | A2MP1 | A4GALT | ABAT | ABCA1 | ABCB1 | ABCB6 | ABCC5 | ABCC9 | ABCF2 | ABCG2 | ABHD11-AS1 | ABHD3 | ABI1 | ABI2 | ACAA1 | ACACA | ACAN | ACE | ACE2 | ACE3P | ACOT8 | ACP5 | ACSF3 | ACTA2-AS1 | ACTBP12 | ACTG1P12 | ACTG1P22 | ACTL10 | ACTN1-DT | ACTR1A | ACTR1B | ACTR2 | ACTR3 | ACVR2B-AS1 | ADA | ADAD2 | ADAL | ADAM1B | ADAM22 | ADAM8 | ADAMTS15 | ADAMTS16 | ADAMTS17 | ADAMTS18 | ADAMTS19 | ADAMTS9-AS2 | ADAMTSL4 | ADCY4 | ADD1 | ADD2 | ADD3 | ADD3-AS1 | ADGRA3 | ADGRE2 | ADGRF3 | ADGRG2 | ADGRL1-AS1 | ADIPOQ-AS1 | ADM5 | ADPGK-AS1 | AEBP1 | AFF1-AS1 | AFG3L1P | AFM | AFP | AFTPH | AGA | AGAP1-IT1 | AGAP11 | AGAP2-AS1 | AGAP4 | AGER | AGL | AGO3 | AGO4 | AGRP | AGT | AGTR1 | AGTR2 | AGXT | AHCY | AHI1 | AHR | AIF1 | AK6P1 | AKAP9 | AKR1C1 | AKR1C2 | AKT1 | AKT3 | ALDH1L1-AS1 | ALG14 | ALK | ALKBH4 | ALMS1-IT1 | ALOX12-AS1 | ALOX15P1 | AMN1 | ANAPC16 | ANAPC1P1 | ANKFN1 | ANKIB1 | ANKRD16 | ANKRD20A12P | ANKRD20A13P | ANKRD20A17P | ANKRD22 | ANKRD24 | ANKRD26P3 | ANKRD49 | ANKRD61 | ANKRD63 | ANKRD66 | ANLN | ANO6 | ANTXR2 | ANTXRL | ANTXRLP1 | ANXA1 | ANXA11 | ANXA13 | ANXA2 | ANXA2P1 | ANXA2P2 | ANXA2P3 | ANXA3 | ANXA4 | ANXA5 | ANXA6 | ANXA7 | AOAH | AP1B1 | AP1G1 | AP1M2 | AP1S1 | AP2A2 | AP2B1 | AP2M1 | AP2S1 | AP3S1 | AP4B1-AS1 | APBB1IP | APCDD1L | APELA | APLNR | APOBEC3A_B | APOBEC3B-AS1 | APOBEC3H | APOC4-APOC2 | APOOP2 | APPAT | APTR | AR | ARAP1-AS2 | ARFRP1 | ARHGAP19-SLIT1 | ARHGAP22-IT1 | ARHGAP26-AS1 | ARHGAP26-IT1 | ARHGAP31-AS1 | ARHGEF26-AS1 | ARHGEF33 | ARHGEF38 | ARHGEF38-IT1 | ARHGEF7-AS1 | ARID2 | ARID3A | ARL14EP | ARL15 | ARL17B | ARL2-SNX15 | ARL4A | ARL4C | ARLNC1 | ARMCX4 | ARMCX5-GPRASP2 | ARMCX6 | ARPC1B | ARPC2 | ARPC3 | ARPC4 | ARPC4-TTLL3 | ARPC5 | ARPIN-AP3S2 | ARRDC3-AS1 | ARX | ASAP1-IT2 | ASNSD1 | ASPN | ASTN2-AS1 | ASXL1 | ATAD2B | ATE1-AS1 | ATF4P4 | ATM | ATN1 | ATP11A-AS1 | ATP13A5-AS1 | ATP2A1-AS1 | ATP5PBP5 | ATP5PO | ATP6AP1 | ATP6AP2 | ATP6V0A1 | ATP6V0B | ATP6V0CP1 | ATP6V0E1P1 | ATP6V1FNB | ATP6V1G2 | ATP6V1G2-DDX39B | ATP7A | ATP7B | ATP8B1-AS1 | ATP9A | ATR | ATRX | B3GALT9 | B3GNT6 | BAALC-AS1 | BABAM2-AS1 | BACE1-AS | BANCR | BAX | BBS12 | BCAP31 | BCAR3-AS1 | BCAS2P2 | BCAS3 | BCL11A | BCL2 | BCL2L1 | BCL2L10 | BCL2L11 | BCL2L2-PABPN1 | BCO1 | BCRP7 | BECN1 | BEST2 | BHLHA15 | BHLHE40-AS1 | BICRA | BIVM | BIVM-ERCC5 | BLACAT1 | BLOC1S1-RDH5 | BLOC1S5-TXNDC5 | BMPER | BMPR1B-DT | BMS1P17 | BMS1P21 | BMS1P7 | BNC2 | BOK-AS1 | BOLA3-DT | BORCS5 | BORCS6 | BORCS7 | BORCS7-ASMT | BPIFB5P | BRAF | BRCA1 | BRINP1 | BRWD1 | BSN-DT | BSPH1 | BSPRY | BTBD1 | BTBD16 | BTG4 | BTN2A3P | BTNL10P | BYSL | C10orf71 | C10orf71-AS1 | C10orf90 | C10orf95-AS1 | C11orf24 | C11orf71 | C11orf91 | C13orf46 | C16orf82 | C16orf95 | C17orf107 | C17orf99 | C18orf54 | C1orf68 | C1QBP | C1QL2 | C1QTNF1-AS1 | C1QTNF3-AMACR | C20orf181 | C21orf58 | C21orf62-AS1 | C21orf91 | C2CD4D | C2CD4D-AS1 | C4B_2 | C4orf46P3 | C5orf52